Adamis Pharmaceuticals (NASDAQ: ADMP) and BioDelivery Sciences International (NASDAQ:BDSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Adamis Pharmaceuticals and BioDelivery Sciences International, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals 0 0 3 0 3.00
BioDelivery Sciences International 0 1 5 0 2.83

Adamis Pharmaceuticals presently has a consensus price target of $10.33, indicating a potential upside of 124.64%. BioDelivery Sciences International has a consensus price target of $4.50, indicating a potential upside of 60.71%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Adamis Pharmaceuticals is more favorable than BioDelivery Sciences International.

Volatility and Risk

Adamis Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Institutional and Insider Ownership

16.7% of Adamis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.2% of BioDelivery Sciences International shares are held by institutional investors. 9.6% of Adamis Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of BioDelivery Sciences International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Adamis Pharmaceuticals and BioDelivery Sciences International’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adamis Pharmaceuticals $6.47 million 23.74 -$19.43 million N/A N/A
BioDelivery Sciences International $15.55 million 10.06 -$67.13 million ($0.19) -14.74

Adamis Pharmaceuticals has higher earnings, but lower revenue than BioDelivery Sciences International.

Profitability

This table compares Adamis Pharmaceuticals and BioDelivery Sciences International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals -143.15% -57.74% -42.37%
BioDelivery Sciences International 10.40% 33.83% 6.43%

Summary

BioDelivery Sciences International beats Adamis Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.